Statistiques
- Consultations du résumé : 85
- Article intégral : 70
depuis 30/03/2011
Services
-
Articles des mêmes auteurs
- PubMed - Recommander cet article
- Exporter cette référence
Accès gratuit
|
|||||||||||||||||||||
- Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103 : 907–14.
- Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7 : 847–52.
- Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res 1996; 26 : 262–7.
- Van Haperen R, van Tol A, Vermeulen P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20 : 1082–8.
- Desrumaux C, Deckert V, Athias A, et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J 1999; 13 : 883–92.
- Jiang XC, Qin S, Lin M, et al. Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice. Circulation 2001; 104 : II–232.

BibSonomy
CiteUlike
Del.icio.us
Digg
Facebook
Mendeley
Twitter